Please assess the completion status of the following clinical trial:

Trial Title: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with the diagnosis of ITP according to the International Working Group (IWG) guidelines~* failure to splenectomy or at least four standard ITP-specific treatments, but not necessarily undergone splenectomye~* baseline peripheral platelet count less than 30,000/uL or the presence of bleeding symptoms~* need of treatment(s) (including, but not limited to, low dose of corticosteroids) to minimize the risk of clinically significant bleeding. Need of on-demand or~Exclusion Criteria:~* secondary ITP~* pregnancy~* hypertension~* cardiovascular disease~* diabetes~* liver and kidney function impairment~* HCV, HIV, HBsAg seropositive status~* patients with systemic lupus erythematosus and/or antiphospholipid syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).